Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04991025 · ClinicalTrials.gov registry record · Phase 2

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

A Phase 2 study of Lung Cancer and Lung Cancer Stage II, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
7
Study locations

NCT04991025 is a Phase 2 study of Lung Cancer and Lung Cancer Stage II that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 60 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (94% lower). The trial reports 7 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04991025, a Phase 2 study of Lung Cancer and Lung Cancer Stage II, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
7
Study locations

Study Summary

The purpose of the study is to explore adding the study drug certolizumab to standard chemotherapy as it may reduce the inflammation caused by the cancer and make the chemotherapy more effective in shrinking the cancer. This study will examine whether adding certolizumab to the usual treatment approach is better than, the same as, or worse than the usual approach alone.

Conditions Studied

Lung Cancer Lung Cancer Stage II Lung Cancer Stage III

Interventions

  • DRUG Carboplatin
  • DRUG Cisplatin
  • DRUG Pemetrexed
  • DRUG Gemcitabine
  • DRUG Certolizumab

Study Locations (7)

New York

  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activity) - Commack
  • Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale

New Jersey

  • Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2022-10-19
Est. Completion 2026-10
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04991025

The ClinicalTrials.gov registry entry for NCT04991025 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT04991025 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.

Frequently Asked Questions

What is clinical trial NCT04991025 about?

NCT04991025 is a clinical study titled "Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery". The purpose of the study is to explore adding the study drug certolizumab to standard chemotherapy as it may reduce the inflammation caused by the cancer and make the chemotherapy more effective in shrinking the cancer. This study will examine whether adding certolizumab to the usual treatment appro...

What is the current status of trial NCT04991025?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2022-10-19. Estimated completion is 2026-10.

What conditions does trial NCT04991025 study?

This clinical trial studies the following conditions: Lung Cancer, Lung Cancer Stage II, Lung Cancer Stage III.

What interventions are being tested in trial NCT04991025?

The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Gemcitabine (DRUG), Certolizumab (DRUG).

Who is sponsoring clinical trial NCT04991025?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04991025 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

Lung Cancer Stage II

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.